| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary biological target of Tau tracer 1 is aggregated tau protein, which forms neurofibrillary tangles in Alzheimer's disease and other tauopathies. The compound binds selectively to tau aggregates over amyloid-beta plaques, providing high specificity for tau pathology. Its binding affinity to tau aggregates has been characterized, and it is designed to cross the blood-brain barrier for PET imaging applications. The selective detection of tau aggregates allows for differentiation between tauopathies and other neurodegenerative conditions.
|
|---|---|
| ln Vitro |
Tau tracer 1 (compound 13) can be used with Positron Emission Tomography (PET) imaging to selectively detect Tau aggregate-associated illnesses and abnormalities, such as Alzheimer's disease and other tauopathies[1].
In vitro, Tau tracer 1 (compound 13) effectively detects tau-related disorders and abnormalities associated with tau aggregates using PET imaging. The compound demonstrates selective binding to tau aggregates in brain tissue sections from patients with Alzheimer's disease and other tauopathies. Its binding properties have been characterized using in vitro competitive binding assays against 3R/4R tau aggregates. The compound shows rapid brain uptake and washout kinetics suitable for neuroimaging applications. |
| ln Vivo |
Information regarding the in vivo activity of Tau tracer 1 in animal models is limited. In vivo PET imaging studies with related tau tracers have shown brain uptake and kinetics suitable for neuroimaging in healthy rats. The compound is designed for use as a diagnostic imaging agent rather than a therapeutic agent, so traditional efficacy endpoints such as tumor growth inhibition are not applicable. Its primary in vivo application is the visualization and quantification of tau pathology in the brain.
|
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for Tau tracer 1 involves measuring its binding affinity to aggregated tau protein. This can be performed using a competitive binding assay with brain tissue homogenates from Alzheimer's disease patients or with synthetic tau fibrils. The compound is incubated with tau aggregates in the presence of a radiolabeled reference tracer, and its ability to displace the reference tracer is measured. The binding affinity (Kd or Ki) is determined from the competition curve.
|
| Cell Assay |
The in vitro cellular assay for Tau tracer 1 involves the use of brain tissue sections from patients with tauopathies or cell models expressing tau aggregates. The compound is incubated with the tissue sections, and its binding is visualized using fluorescence microscopy or autoradiography. The selectivity for tau over amyloid-beta is assessed by comparing binding in brain regions with tau pathology versus amyloid plaques. These assays are used to characterize the binding properties of the tracer.
|
| Animal Protocol |
The in vivo animal experiment workflow for Tau tracer 1 involves the use of rodent models of tauopathy or healthy animals for pharmacokinetic studies. The compound is administered intravenously, and PET imaging is performed at various time points to assess brain uptake, distribution, and washout kinetics. The specificity of the tracer for tau aggregates is confirmed by comparing imaging results with post-mortem histopathology. These studies are essential for evaluating the tracer's suitability for human use.
|
| References |
| Molecular Formula |
C34H23N5O2
|
|---|---|
| Molecular Weight |
533.58
|
| Exact Mass |
533.185
|
| CAS # |
2173353-53-0
|
| PubChem CID |
139447284
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.1
|
| tPSA |
89.4
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
41
|
| Complexity |
831
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)N4C5=C(C=NC=C5)C6=C4N=C(C=C6)C7=CC(=NC=C7)[N+](=O)[O-]
|
| InChi Key |
AURLAHXEHOEQMJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H23N5O2/c40-39(41)32-22-24(18-21-36-32)30-17-16-28-29-23-35-20-19-31(29)38(33(28)37-30)34(25-10-4-1-5-11-25,26-12-6-2-7-13-26)27-14-8-3-9-15-27/h1-23H
|
| Chemical Name |
11-(2-nitropyridin-4-yl)-8-trityl-4,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8741 mL | 9.3707 mL | 18.7413 mL | |
| 5 mM | 0.3748 mL | 1.8741 mL | 3.7483 mL | |
| 10 mM | 0.1874 mL | 0.9371 mL | 1.8741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.